Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29969056 | 1.00 | AURKA (0.52) | AURKARPS6KB1LOXL2SIRT2HDAC3 | |
| Hydrochloric Acid SCHEMBL307872 | 0.99 | AURKA (0.51) | AURKARPS6KB1LOXL2SIRT2HDAC3 | |
| SCHEMBL31370757 | 0.89 | AURKA (0.50) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL2245914 | 0.87 | AURKA (0.42) | AURKARPS6KB1LOXL2CFDCA1 | |
| SCHEMBL4699624 | 0.87 | CA1 (0.51) | AURKARPS6KB1LOXL2SIRT2CFD | |
| SCHEMBL8711740 | 0.87 | AURKA (0.50) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL31139332 | 0.87 | PDK1 (0.58) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL29991279 | 0.87 | MAPT (0.54) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL1858721 | 0.87 | PDK1 (0.58) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL1985668 | 0.87 | MAPT (0.54) | AURKARPS6KB1SIRT2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339406-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-11-06 | — | — | US | disclosed |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2025-10-23 | — | — | US | disclosed |
| US-12364688-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-07-22 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-13 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4461715-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| CN-1514823-A | Oxalic acid derivatives | Ĭ��ר���ɷ�����˾ | 2004-07-21 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | disclosed |
| WO-1998014451-A1 | FUSED PYRAZOLE DERIVATIVE AND PROCESS FOR ITS PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| WO-1998014449-A1 | FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | AURKA 728/4885RPS6KB1 531/4885LOXL2 1671/4885 |
| US-12364688-B2 | NSD family inhibitors and methods of treatment therewith | NSD3, NSD2, NSD1 | AURKA 3088/4885RPS6KB1 2812/4885LOXL2 2762/4885 |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | AURKA 4094/4885RPS6KB1 328/4885LOXL2 1399/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | AURKA 47/4885RPS6KB1 2055/4885LOXL2 4427/4885 |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BPGM, PNMT, DDT | AURKA 2727/4885RPS6KB1 1201/4885LOXL2 1146/4885 |
| US-20250084012-A1 | METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP | TERT, MGMT, MITF | AURKA 3035/4885RPS6KB1 2656/4885LOXL2 965/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | AURKA 3788/4885RPS6KB1 369/4885LOXL2 3557/4885 |
| US-20250339406-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | AURKA 3088/4885RPS6KB1 2812/4885LOXL2 2762/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | AURKA 2614/4885RPS6KB1 2261/4885LOXL2 3329/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | AURKA 3003/4885RPS6KB1 524/4885LOXL2 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.